...
机译:早期不良事件对vemurafenib或vemulafenib plus cobimetinib治疗的晚期黑色素瘤患者的反应和生存结果的影响:临床试验数据的汇总分析
Flinders Centre for Innovation in Cancer &
Department of Clinical Pharmacology College of Medicine and Public Health Flinders University Adelaide South Australia Australia;
Flinders Centre for Innovation in Cancer &
Department of Clinical Pharmacology College of Medicine and Public Health Flinders University Adelaide South Australia Australia;
Flinders Centre for Innovation in Cancer &
Department of Clinical Pharmacology College of Medicine and Public Health Flinders University Adelaide South Australia Australia;
Flinders Centre for Innovation in Cancer &
Department of Clinical Pharmacology College of Medicine and Public Health Flinders University Adelaide South Australia Australia;
adverse events; cobimetinib; prediction; response; survival; vemurafenib;
机译:早期不良事件对vemurafenib或vemulafenib plus cobimetinib治疗的晚期黑色素瘤患者的反应和生存结果的影响:临床试验数据的汇总分析
机译:日常临床实践中vemurafenib,Ipilimumab和dabrafenib治疗患者存活的分析(现实世界数据):2013 - 2016年波兰药物/报销课程患者回顾性分析
机译:由于不良事件,用Nivolumab和Ipilimalab停止治疗的先进黑素瘤患者的疗效和安全结果:随机期II和III试验的汇总分析
机译:基于机器学习的不良结果预测的大型临床试验数据建模:死亡事件的案例研究
机译:将计算机断层扫描(CT)成像反应标准和纹理分析测量值与接受抗血管生成治疗的转移性黑色素瘤患者的生存率相关联。
机译:初步治疗和预后因素对耐伽罗唑或vemulafenib±Cobimetinib治疗的BRAF突变转移性黑素瘤中的后进口生存的影响:四种临床试验的合并分析
机译:严重皮疹的危险因素单独使用vemureafenib或与高级黑素瘤的Cobimetinib组合:临床试验的汇总分析